1 / 17

Sponsored by Keele University

A utologous A utologous C hondrocyte T ransplantation/ I mplantation V ersus E xisting treatments ISCRCTN 48911177. A multicentre orthopaedic surgical RCT involving over 25 UK centres and 2 Norwegian centres. Sponsored by Keele University

hina
Download Presentation

Sponsored by Keele University

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AutologousAutologousChondrocyteTransplantation/ImplantationVersusExisting treatmentsISCRCTN 48911177 A multicentre orthopaedic surgical RCT involving over 25 UK centres and 2 Norwegian centres Sponsored by Keele University Lead centre: Robert Jones & Agnes Hunt Orthopaedic Hospital NHS Trust in collaboration with the University of Birmingham

  2. Overview • Aims of ACTIVE • ACTIVE Collaborators • Trial Design • Progress • Ongoing Challenges

  3. Primary Aim • Primary Aim • To determine whether ACI offers longer-term benefits than the “best alternative” non-ACI treatment for repairing chondral defects in the knee that remain symptomatic following previous treatment

  4. Secondary Aims • Secondary Aims: • To compare the use of periosteum with a manufactured membrane • To assess and compare the cost effectiveness of ACI vs non-ACI option and periosteum vs membrane

  5. Funding / Support • MRC grant for research costs • e.g. trial manager, local co-ordinators, assessors, travel & training, materials • DoH funds excess treatment costs • - to meet cost difference bt. ACI vs. non ACI option • NHS Service Support Costs are available • - for clinic resources per patient formally registered • - per follow-up outpatient visit at 6 mts, 3, 5, & 10 yrs • - for serology tests on control patients • Membrane donated by Geistlich • -any cell supplier can be used

  6. Collaborating Surgeons-UK & Norway Each centre has at least one surgeon and a study co-ordinator and independent assessor

  7. Surgeons’ Training Workshop

  8. Trial Design • Patients randomised to: • ACI/MACI or Surgeons’ best non-ACI choice • ACI arm randomised to (this is now optional) • periosteum or collagen membrane • patch patch

  9. Patient Eligibility • Isolated symptomatic chondral or osteochondral defect(s) in the knee • Meets the “uncertainty principle” • Previous failed treatment on same defect ≥ 6 mts earlier (may include arthroscopic washout) • Exclusions: • Bilateral defects, kissing lesions, defects >12cm2, total meniscectomy, patella malaligment, generalised osteoarthritis, patients with low probability of compliance with rehab & follow-up

  10. Summary of Data (March ’07 N=147) • 142 patients randomised • ACI Standard • Periosteum 36Microfracture 57 • Chondro-gide 35 Mosaicplasty 7 Debridement 5 • Drilling 2 • AMIC 1 95 men: 47 womenmean age 38 years old4 crossed over from ACI to standard2 withdrawn9 had additional procedures65 with 1 year follow-up

  11. Outcome Measures“robust & relevant data” • Primary Outcome Measure: • “Cessation of benefit” • – Combination of questionnaires & independent • blinded assessments over 10 years follow-up • Secondary Outcome Measures: • – Health Economics: QALYs estimated for each arm • from a societal perspective • – Cininnati Sports Activity Scale • – IKDC Subjective Knee Evaluation Form

  12. Independent Assessment

  13. Recruitment Progress (April ‘08) TotalPatients randomised = 208

  14. Further recruitment • Surgeons at RNOH, Stanmore have joined the trial and are ready to start • Will enable 480 patients to be recruited by end of 2009

  15. Further Information • Prof. James Richardson, Chief Investigator – tel: 01691 404386 • Talk to Heather Smith, Trial Manager • Heatherj.smith@rjah.nhs.uk Visit the website:www.active-trial.org.uk

  16. www.active-trial.org.uk

  17. Acknowledgements • Trial Steering Committee: • Prof. Neil Rushton (Orthopaedic Research Unit, Cambridge) • Dr Martin Landray (Clinical Trial Service Unit, Oxford) • Prof. Richard Gray (Birmingham Clinical Trials Unit) • Prof. James Richardson (RJAH Orthopaedic Hospital) • Prof. George Bentley (RNOH, Stanmore) • Prof. Marilyn James (Liverpool John Moores University) • Data Monitoring & Ethics Committee: • Prof. Hamish Simpson (Dept. Orthopaedics, Edinburgh Uni) • Dr Paresh Jobanputra (Dept. Rheumatology, B’ham Uni) • Dr Emma Hall (Institute of Cancer Research, Surrey)

More Related